ArticleCureus2025
Effectiveness and Safety of Transdermal Buprenorphine for Acute Postoperative Pain Management Following Mandibular Resection: A Prospective Observational Study.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Managing postoperative pain after mandibular excision and reconstruction remains challenging, and using conventional opioid medications has a risk of side effects. Objective This study aimed to evaluate the effectiveness and safety of the transdermal buprenorphine patch in managing postoperative acute pain following mandibular resection and reconstruction in a real-world clinical setting. Methodology A prospective, observational study was conducted, involving 108 patients who underwent mandibular resection or reconstruction between January and December 2023. Following surgery, participants received transdermal buprenorphine patches, and the visual analog scale (VAS) was used to measure pain severity at baseline and 6, 12, 24, and 48 hours after application. Additionally, documented were adverse effects, the usage of rescue analgesia, and patient satisfaction. The data was examined using paired t-tests. Results The average VAS pain score before surgery was 7.83 ± 1.27, however, it dropped dramatically to 5.24 ± 1.35 after six hours, 4.18 ± 1.28 at 12 hours, 3.07 ± 1.10 at 24 hours, and 2.23 ± 1.05 at 48 hours. Nausea (9.26%) and dizziness (5.56%) were the most frequent side effects, with 74.07% of patients reporting no negative symptoms. 70.37% of patients did not need any rescue analgesics, and 85.19% of patients expressed satisfaction or high satisfaction with the way their pain was managed. Significant pain reductions were seen at all time periods using paired t-tests (p < 0.001). Conclusion The transdermal buprenorphine patch is a safe and effective alternative for managing acute postoperative pain following mandibular surgery.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.